logo

Atossa Therapeutics Inc. (ATOS)



Trade ATOS now with
  Date
  Headline
11/10/2020 10:06:13 AM Atossa : Preliminary Phase 1 Study Shows Safety And Tolerability Of AT-301 Nasal Spray Being Developed For COVID-19
10/19/2020 10:16:06 AM Atossa Completes Enrollment Of Phase 1 Study Of AT-301 Nasal Spray Being Developed For Coronavirus Causing COVID
9/17/2020 9:38:42 AM Atossa Receives Second Positive Interim Safety Assessment In Study Of AT-301 Nasal Spray
8/3/2020 9:43:21 AM Atossa Gets Australian Govt Approval To Open Clinical Study Of AT-301 Nasal Spray Being Developed To Treat COVID-19
7/30/2020 9:34:07 AM Atossa Reports Interim Findings Following 18 Months Of Expanded Access Study Of Endoxifen
7/15/2020 10:08:30 AM Atossa Announces Successful Results From In Vitro Testing Of AT-301, Proprietary COVID-19 Nasal Spray Drug Candidate
6/11/2020 9:33:30 AM Atossa Therapeutics Reports Availability Of Manuscript On Results From In Vitro Testing Of COVID-19 Drug, AT-H201
5/7/2020 9:37:30 AM Atossa Report Positive Interim Results From Phase 2 Study Of Oral Endoxifen
4/20/2020 8:18:12 AM Atossa Seeks Clinical Investigation Approval To Launch COVID-19 HOPE Study
4/2/2020 8:14:49 AM Atossa Report Recent Progress With Phase 2 Study Administering Oral Endoxifen
3/2/2020 8:41:30 AM Atossa Files For Swedish Regulatory Approval To Begin Phase 2 Study Of Endoxifen
1/6/2020 8:16:43 AM Atossa Genetics Changes Corporate Name To Atossa Therapeutics, Inc.
12/19/2019 8:39:55 AM Atossa Genetics Contracts With Stockholm South General Hospital For Endoxifen
10/16/2019 8:37:55 AM Atossa Genetics Receives IRB Approval For Phase 2 Breast Cancer Study Using Intraductal Technology